Impact of the 2004 food and drug administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression

Medical Care

Volumn 48, Issue 11, 2010, Pages 947-954

  Valluri, Satish ^a   Zito, Julie M ^a   Safer, Daniel J ^b   Zuckerman, Ilene H ^a   Mullins, C Daniel ^a   Korelitz, James J ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c WESTAT   (United States)

Author keywords

antidepressants; FDA; FDA warning; mental health; pediatric depression; SSRI; suicidality

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; SERTRALINE; TRAZODONE; TRIMIPRAMINE; VENLAFAXINE;

ADOLESCENT; AMBULATORY CARE; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CHILD; CLINICAL DECISION MAKING; COHORT ANALYSIS; CONDUCT DISORDER; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; FACTUAL DATABASE; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH INSURANCE; HUMAN; INDEPENDENT VARIABLE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NEW ONSET DEPRESSION; ONSET AGE; OPPOSITIONAL DEFIANT DISORDER; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOTHERAPY; SCHOOL CHILD; SUICIDAL IDEATION; UNITED STATES;

ADOLESCENT; ADOLESCENT BEHAVIOR; ADVISORY COMMITTEES; AGE OF ONSET; ANTIDEPRESSIVE AGENTS; CHILD; CHILD BEHAVIOR; CHILD, PRESCHOOL; DEPRESSIVE DISORDER, MAJOR; DRUG LABELING; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; MALE; ODDS RATIO; PEDIATRICS; PHYSICIAN'S PRACTICE PATTERNS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SUICIDE, ATTEMPTED; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78049328961     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181ef9d2b     Document Type: Article

References (25)

1. FDA. FDA public health advisory: reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD). October 27, 2003. Available at: http://www.fda. gov/cder/drug/advisory/mdd.htm. Accessed June 19, 2007.
2. FDA. FDA public health advisory: worsening depression and suicidality in patients being treated with antidepressant, 2004. Available at: http:// www.fda.gov/cder/drug/antidepressants/AntidepressanstPHA.htm. Accessed June 21, 2007.
3. FDA. FDA news: FDA launches a multi-pronged strategy to strengthen safeguards for children treated with antidepressant medications. Available at: http://www.fda.gov/bbs/topics/news/2004/NEW01124.html. Accessed June 21, 2007.
4. Kurian BT, Ray WA, Arbogast PG, et al. Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Arch Pediatr Adolesc Med. 2007;161:690-696.
5. Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry. 2007;164:884-891.
6. Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry. 2007;64:466-472.
7. Olfson M, Marcus SC, Druss BG. Effects of food and drug administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry. 2008;65:94-101.
8. Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry. 2009;66:633-639.
9. Pamer C, Kaplan S, Wu YT, et al. Changes in US antidepressant and antipsychotic prescription patterns in the time period following FDA actions. Pharmacoepidemiol Drug Saf. 2008;17:662-663.
10. Thomason C, Riordan H, Schaeffer J, et al. A review of antidepressant prescribing practices in a large national managed care database of pediatric patients prior to and after black-box warnings [abstract]. J Child Adolesc Psychopharmacol. 2006;16:662-663.
11. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297:1683.
12. Elias M. Add suicide warnings on antidepressant labels, FDA warns. USA Today. March 23, 2004:7D.
13. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-920.
14. Rost K, Dickinson LM, Fortney J, et al. Clinical improvement associated with conformance to HEDIS-based depression care. Ment Health Serv Res. 2005;7:103-112.
15. DeBar LL, Clarke GN, O'Connor E, et al. Treated prevalence, incidence, and pharmacotherapy of child and adolescent mood disorders in an HMO. Ment Health Serv Res. 2001;3:73-89.
16. Birmaher B, Brent D, AACAP Work Group on Quality Issues, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007;46:1503-1526.
17. Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and adolescents: a meta-analysis. Psychol Bull. 2006;132:132-149.
18. Safer DJ. Should selective serotonin reuptake inhibitors be prescribed for children with major depressive and anxiety disorders? Pediatrics. 2006;118:1248-1251.
19. Wagner KD, Jonas J, Findling RL, et al. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry. 2006;45:280-288.
20. Zuckerman IH, Lee E, Wutoh AK, et al. Application of regression- discontinuity analysis in pharmaceutical health services research. Health Serv Res. 2006;41:550-563.
21. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44:1049-1060.
22. Ma J, Lee KV, Stafford RS. Depression treatment during outpatient visits by U.S. children and adolescents. J Adolesc Health. 2005;37:434-442.
23. Mojtabai R, Olfson M. National trends in psychotherapy by office-based psychiatrists. Arch Gen Psychiatry. 2008;65:962-970.
24. Olfson M, Marcus SC, Druss B, et al. National trends in the use of outpatient psychotherapy. Am J Psychiatry. 2002;159:1914-1920. (Pubitemid 35283259)
25. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292:807-820. (Pubitemid 39079667)